HONG KONG – Beijing-based Beigene Ltd. struck its second deal outside China this year, signing an option and license agreement with Boston Immune Technologies & Therapeutics Inc. (BITT) for the latter’s tumor necrosis factor receptor 2 (TNFR2) antagonist antibodies. Beigene will exclusively develop, manufacture and commercialize BITT’s TNFR2 antagonist antibodies in Asia, excepting Japan, Australia and New Zealand.
Athenex Inc.’s launch of Klisyri (tirbanibulin) likely whetted investor appetite for another prospect coming down the pike: Oraxol, an oral form of paclitaxel for which the Buffalo, N.Y.-based firm has been assigned a PDUFA date of Feb. 28.
As expected, G1 Therapeutics Inc.’s Cosela (trilaciclib) won FDA approval for use in extensive-stage small-cell lung cancer patients undergoing chemotherapy, becoming the first proactively administered myelopreservation therapy to hit the market.
Shares of Bluebird Bio Inc. (NASDAQ:BLUE) fell 37.8% to $28.44 on Feb. 16 as the company temporarily suspended two trials of its experimental gene therapy for sickle cell disease, Lentiglobin (BB-1111), while investigating one unexpected case of acute myeloid leukemia (AML) and another of myelodysplastic syndrome among participants in a phase I/II study of the candidate, called HGB-206. A second patient experienced MDS in 2018.
DUBLIN – Cellectis SA is picking up $15 million worth of equity in Cytovia Therapeutics Inc. and could earn as much as $760 million in development, regulatory and sales milestones from a deal involving up to five gene-edited allogeneic natural killer (NK) cell or chimeric antigen receptor (CAR-NK) cell therapies employing its Talen (transcription activator-like effector nuclease) gene editing technology.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology Genitourinary Cancers Symposium, including: Astellas, Eisai, Exelixis, Immunity, Merck & Co., Seagen.
Molecular Templates Inc., of Austin, Texas, has signed an R&D collaboration with Bristol Myers Squibb Co. (BMS) worth $70 million up front and potential development, regulatory and sales milestone payments of up to $1.3 billion. Molecular Templates will work on therapies designed for unnamed oncology targets to kill targeted cells by forcing receptor internalization, delivering payloads and enzymatically inactivating ribosomes.
Twenty years to the month after the completion of the draft sequence of the human genome, the Human Genome Project and follow-on projects like The Cancer Genome Atlas are underpinning advances in precision medicine.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology Genitourinary Cancers Symposium, including: Aveo, Cardiff, Clovis, Essa, Infinity, Noxopharm.
Panbela Therapeutics Inc. hit a speed bump with its phase I trial in the ever-challenging indication of pancreatic cancer (PC), as an independent data safety monitoring board (DSMB) recommended that dosing be held for patients until more safety information is available about polyamine analog SBP-101.
RSS
